NuGenerex Immuno-Oncology, Inc. (NUGX) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

NuGenerex Immuno-Oncology, Inc. (NUGX) Healthcare & Pipeline Overview

NuGenerex Immuno-Oncology, Inc. is a biotechnology firm specializing in cancer immunotherapy, particularly the development of peptide vaccines like AE37. Currently in Phase II trials for triple-negative breast cancer, the company aims to modulate the immune system to combat cancer, operating within the competitive biotechnology landscape.

What Is the Investment Thesis for NUGX?

NuGenerex Immuno-Oncology's investment thesis hinges on the successful development and commercialization of its lead product, AE37. The Phase II clinical trials for metastatic triple-negative breast cancer represent a critical milestone. Positive trial results could significantly increase the company's valuation. The company's small size and limited resources present both opportunities and risks. The company's gross margin is 78.2%, but the profit margin is -1252.7%. The company's beta is -19.93. The company's market capitalization is $0.00B. The company's P/E ratio is -0.00. The company does not pay dividends. The company's future success depends on securing additional funding and partnerships to support ongoing clinical trials and future commercialization efforts. The company's success is tied to the clinical trial outcomes and regulatory approvals.

Based on FMP financials and quantitative analysis

NUGX Key Highlights

AE37 is in Phase II clinical trials for metastatic triple-negative breast cancer, representing a key milestone for the company.

• Gross margin of 78.2% indicates strong potential profitability if products reach commercialization.
• Negative profit margin of -1252.7% reflects ongoing R&D expenses and lack of revenue-generating products.
• Market capitalization of $0.00B indicates the company is a micro-cap stock with high growth potential and associated risks.
• The company's beta is -19.93, indicating that the stock price moves in the opposite direction of the market.

Who Are NUGX's Competitors?

NUGX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NUGX's Key Strengths?

Proprietary peptide-based immunotherapy technology.

• AE37 in Phase II clinical trials for triple-negative breast cancer.
• Experienced management team with expertise in cancer immunotherapy.
• Subsidiary of Generex Biotechnology Corporation.

What Are NUGX's Weaknesses?

Limited financial resources.

• Dependence on the success of AE37.
• Small number of employees.
• High R&D expenses.

What Could Drive NUGX Stock Higher?

Data readout from Phase II clinical trials for AE37 in metastatic triple-negative breast cancer.

• Potential for strategic partnerships with larger pharmaceutical companies.
• Development of new immunotherapeutic products and vaccines beyond AE37.

What Are the Key Risks for NUGX?

Financial-distress signal — its Altman Z-Score of -17.55 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for AE37.
• Regulatory hurdles and delays in obtaining FDA approval.
• Competition from other biotechnology companies developing cancer immunotherapies.
• Limited financial resources and dependence on external funding.

What Are the Growth Opportunities for NUGX?

• Successful completion of Phase II clinical trials for AE37 in metastatic triple-negative breast cancer could lead to accelerated regulatory approval and commercialization. The market for triple-negative breast cancer treatments is substantial, with a growing need for more effective therapies. Positive trial data could attract partnerships with larger pharmaceutical companies, providing financial resources and expertise to support further development and commercialization. Timeline: Anticipated data readout within the next 12-18 months.
• Expansion of AE37's application to other cancer types beyond triple-negative breast cancer represents a significant growth opportunity. The company could explore the potential of AE37 in other solid tumors or hematological malignancies, expanding its target market and diversifying its product pipeline. This would require additional preclinical and clinical studies to demonstrate efficacy and safety in new indications. Timeline: Initiation of new clinical trials within the next 2-3 years.
• Development of new immunotherapeutic products and vaccines beyond AE37 could drive long-term growth. The company could leverage its expertise in peptide-based immunotherapy to develop novel treatments for other cancers or infectious diseases. This would require significant investment in research and development, but could lead to the creation of a broader product portfolio and increased revenue streams. Timeline: Identification of new drug candidates within the next 3-5 years.
• Strategic partnerships with larger pharmaceutical companies or biotechnology firms could provide access to additional funding, expertise, and commercialization capabilities. Collaborations could focus on co-development of AE37 or other pipeline products, or on licensing agreements for specific markets. Such partnerships could accelerate the company's growth and reduce its financial risk. Timeline: Potential partnership agreements within the next 12-24 months.
• Expansion into new geographic markets, particularly in Asia and Europe, could drive revenue growth. The company could seek regulatory approval for AE37 in these regions and establish commercial partnerships to market and distribute its products. This would require significant investment in regulatory affairs and market access, but could provide access to a larger patient population and increased sales. Timeline: Expansion into new markets within the next 3-5 years.

What Are NUGX's Competitive Advantages?

• Proprietary peptide-based immunotherapy technology.
• Patent protection for AE37 and other pipeline products.
• Clinical data demonstrating the safety and efficacy of AE37.
• Expertise in cancer immunotherapy and peptide vaccine development.

What Does NUGX Do?

NuGenerex Immuno-Oncology, Inc., formerly known as Antigen Express, Inc., was founded in 1993 and is based in Miramar, Florida. The company is dedicated to the research and development of immunotherapeutic products and vaccines designed to treat cancer by modulating the immune system. Their primary focus is on developing innovative cancer treatments using peptide-based immunotherapy. The company's lead product, AE37, is a peptide immunotherapeutic vaccine currently in Phase II clinical trials for the treatment of metastatic triple-negative breast cancer, a particularly aggressive form of the disease. NuGenerex Immuno-Oncology operates as a subsidiary of Generex Biotechnology Corporation, leveraging its parent company's resources and expertise in the biotechnology sector. The company's strategy revolves around harnessing the power of the immune system to target and destroy cancer cells, offering a potentially less toxic and more targeted approach compared to traditional cancer therapies. Their research and development efforts are centered on advancing AE37 through clinical trials and exploring other potential immunotherapeutic candidates. NuGenerex Immuno-Oncology aims to establish itself as a key player in the evolving field of cancer immunotherapy.

What Products and Services Does NUGX Offer?

• Develop immunotherapeutic products for cancer treatment.
• Focus on modulating the immune system to fight cancer.
• Develop peptide immunotherapeutic vaccines.
• Conduct clinical trials to evaluate the safety and efficacy of their products.
• Target specific cancer types, such as metastatic triple-negative breast cancer.
• Seek regulatory approval for their products from agencies like the FDA.

How Does NUGX Make Money?

• Develop and patent novel immunotherapeutic technologies.
• Conduct preclinical and clinical research to validate their products.
• Seek partnerships with larger pharmaceutical companies for funding and commercialization.
• Generate revenue through licensing agreements and product sales, if approved.

What Industry Does NUGX Operate In?

NuGenerex Immuno-Oncology operates within the competitive biotechnology industry, specifically focusing on cancer immunotherapy. This field is characterized by rapid innovation, high regulatory hurdles, and significant investment in research and development. Competitors include companies developing similar immunotherapeutic approaches, such as CHCR (Celcuity Inc.), CRXM (Cardior Pharmaceuticals Inc.), GDBYF (Goldbay Inc.), GLSHQ (Galshri Wellness Inc.), and MGFRF (Medgold Resources Corp.). NuGenerex Immuno-Oncology aims to differentiate itself through its peptide-based vaccine technology and its focus on specific cancer types, such as triple-negative breast cancer.

Who Are NUGX's Key Customers?

• Patients with cancer, particularly metastatic triple-negative breast cancer.
• Healthcare providers who treat cancer patients.
• Pharmaceutical companies seeking to expand their oncology portfolios.
• Research institutions and government agencies involved in cancer research.

Company Profile

NuGenerex Immuno-Oncology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Miramar, US. The company is led by CEO Joseph Moscato. NUGX has traded publicly since 2021.

NuGenerex Immuno-Oncology, Inc. (NUGX) Valuation Context

Relative to its peer group, NUGX's quantitative score of 51/100 is below the peer average of 76/100.

Return on equity for NuGenerex Immuno-Oncology, Inc. stands at 216.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -73.5%, showing how much profit it generates from its asset base. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.

NuGenerex Immuno-Oncology, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -17.55 places it in the distress zone, a signal of elevated financial risk.

NUGX Financials

NUGX Latest News

No recent news available for NUGX.

NUGX Analyst Consensus

NUGX MoonshotScore

NUGX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources